The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd

BSE 524731 · NSE JENBURPH · ISIN INE354A01013 · Group B · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹1,030.55

-1.99%

BSE close, 28 August 2026

Market cap

₹454.81 cr

0.4 cr shares · Micro cap

Free float

₹231.72 cr

as published

P/E · P/B

13.8× · 2.88×

EPS ₹74.39 · BV ₹357.83

FY25-26 rev / PAT

168.74 / 34.74

₹ cr, as filed

Filings, window

15

5 selected · 33%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹944.00 52-WK HIGH ₹1,321.00 ₹1,030.55 23% of range
Against 52-week high-22.0%
Against 52-week low+9.2%
Day change-1.99%
Size bandMicro cap
Index membershipNone

Valuation as published by BSE

Earnings per share₹74.39
Price / earnings13.85×
Price / book2.88×
Book value — derived, price ÷ P/B₹357.83
Return on equity20.81%
Operating margin21.23%
Net margin16.57%

Consistency check

P/B ÷ P/E, which must equal ROE
20.79%
ROE as published
20.81%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 35.51 5.89 13.34 21.23% 16.57%
Mar-26 · Q 44.63 10.85 24.58 32.82% 24.31%
FY25-26 168.74 34.74 78.71 29.68% 20.59%

Quarter on quarter

Revenue, quarter on quarter
-20.4%
Net profit, quarter on quarter
-45.7%
Operating margin, quarter on quarter
-1,159 bps

Disclosure profile 15 filings in the window

0 median 17.0 p75 · 25 sector max 52 15 43th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Change in Management2
Board Outcome1
Change in Directorate1
Results1
Selected sub-total5
Procedural
AGM / EGM3
General2
Newspaper Publication2
Annual Report1
Board Meeting1
Trading Window1
Procedural sub-total10
Total15

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

15 filings · 5 selected · busiest 2026-09-04

Filing rhythm · the twelve most recent

2026-08-042026-09-22

SelectedProcedural

Filings

15 in the window · 3 earlier on record

  1. 22 September 2026 ·

    General

    Intimation Regarding Admission Of Equity Shares Of The Company Under 'Permitted To Trade' Category On National Stock Exchange Of India Limited.

    Intimation regarding admission of Equity shares of the Company under " Permitted to trade" category on National Stock Exchange of India Limited.

    Company Update / General View filing →

  2. 22 September 2026 ·

    Trading Window

    Closure of Trading Window

    Intimation of closure of trading window of the Jenburkt Pharmaceuticals Limited as per the SEBI(Prohibition of Insider Trading) Regulations, 2015.

    Insider Trading / SAST / Closure of Trading Window View filing →

  3. 18 September 2026 ·

    Change in Management

    Change in Management

    Intimation about Resignation of a Senior Management Personnel of the Company.

    Company Update / Change in Management View filing →

  4. 4 September 2026 ·

    Change in Directorate

    Change in Directorate

    Re-Appointment of Shri. Dilip H. Bhuta (DIN 01357252) as Whole Time Director and CFO of the Company for the Period of 05 years from 01st April, 2027 to 31st March, 2032, Approved with requisite ....

    Company Update / Change in Directorate View filing →

  5. 4 September 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Submission of consolidated Voting Results and Scrutinizer's Report on all the Resolutions as set out in the Notice Convening the 41st AGM of the Company held on 04th September, 2026.

    AGM/EGM / AGM View filing →

  6. 4 September 2026 ·

    General

    Proceedings Of The 41St Annual General Meeting Of The Company Held On Friday, 04Th September, 2026.

    Proceedings of the 41st Annual General Meeting of the Company held on Friday, 04th September, 2026.

    Company Update / General View filing →

  7. 4 September 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Summary of the proceedings of the 41st Annual General Meeting of the Company held on Friday, 04th September, 2026.

    AGM/EGM / AGM View filing →

  8. 4 September 2026 ·

    Change in Management

    Change in Management

    Pursuant to Regulation 30 Read with Schedule III of the SEBI(Listing Obligations and Disclosure Requirnments ) Regulations 2015, we hereby inform you about the change in Senior Manaaement ....

    Company Update / Change in Management View filing →

  9. 7 August 2026 ·

    Newspaper Publication

    Newspaper Publication

    Newspaper Publication for standalone Unaudited Financial Results for the quarter ended on 30th June, 2026.

    Company Update / Newspaper Publication View filing →

  10. 6 August 2026 ·

    Results

    Standalone Unaudited Financial Results For The Quarter Ended On 30Th June, 2026.

    Standalone Unaudited Financial Results for the quarter ended on 30th June, 2026.

    Result / Financial Results View filing →

  11. 6 August 2026 ·

    Board Outcome

    Board Meeting Outcome for Outcome Of The Board Meeting Held Today On 06Th August, 2026.

    Outcome of the Board Meeting held today on 06th August, 2026.

    Board Meeting / Outcome of Board Meeting View filing →

  12. 4 August 2026 ·

    Newspaper Publication

    Newspaper Publication

    Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are enclosing herewith clippings of the Newspaper publication for Notice of the 41st AGM of the Company.

    Company Update / Newspaper Publication View filing →

  13. 3 August 2026 ·

    AGM / EGM

    Notice Of The 41St Annual General Meeting Of The Company Schedule To Be Held On Friday, 04Th September, 2026 Through VC/OAVM.

    Notice of the 41st Annual General Meeting of the Company Schedule to be held on Friday, 04th September, 2026, through VC/OAVM.

    AGM/EGM / AGM View filing →

  14. 3 August 2026 ·

    Annual Report

    Reg. 34 (1) Annual Report.

    Submission of the Annual Report for the FY 2025-26, containing Audited Standalone Financial Statements, Auditors Report and Directors Report and the Notice convening 41st Annual General ....

    Others / Reg. 34 (1) Annual Report View filing →

  15. 29 July 2026 ·

    Board Meeting

    Board Meeting Intimation for Considering And Approving Standalone Unaudited Financial Results For The Quarter Ended On 30Th June, 2026.

    Jenburkt Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve standalone unaudited ....

    Board Meeting / Board Meeting View filing →

RSS feed for Jenburkt Pharmaceuticals Ltd · the 50 most recent filings